Overview

Idera’s approach to drug discovery and pipeline of drug candidates have broad potential applications in autoimmune and inflammatory diseases, oncology, respiratory diseases, infectious diseases, hematologic oncology, and as vaccine adjuvants. We seek to advance certain applications through collaborations with pharmaceutical companies. Idera has entered into a collaboration with Merck & Co. for the use of TLR7, 8, and 9 agonists for use as vaccine adjuvants.

Idera welcomes opportunities for collaborations that would apply our technology in additional areas of unmet medical needs with academic or industry collaborators who bring complementary expertise and experience. If you have an interest in a potential collaboration with Idera, please contact us at: bd@iderapharma.com.